IM Cannabis Corp. (IMCC)
USD 1.73
(2.37%)
USD 1.73
(2.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.78 Million CAD | 19.49% |
| 2022 | 11.53 Million CAD | -60.59% |
| 2021 | 29.26 Million USD | 2856.36% |
| 2020 | 990 Thousand CAD | -5.71% |
| 2019 | 1.05 Million CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | -100.0% |
| 2016 | 6441.00 CAD | 8.42% |
| 2015 | 5941.00 CAD | 18.82% |
| 2014 | 5000.00 CAD | -82.76% |
| 2013 | 29 Thousand CAD | -3.33% |
| 2012 | 30 Thousand CAD | -85.0% |
| 2011 | 200 Thousand CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| 2004 | - CAD | 0.0% |
| 2003 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 15.74 Million CAD | 16.2% |
| 2024 Q1 | 13.54 Million CAD | -1.71% |
| 2023 Q1 | 10.01 Million USD | -13.16% |
| 2023 Q2 | 13.28 Million CAD | 32.61% |
| 2023 Q4 | 13.78 Million CAD | 17.99% |
| 2023 FY | 13.78 Million CAD | 19.49% |
| 2023 Q3 | 11.68 Million CAD | -12.05% |
| 2022 Q2 | 36.02 Million CAD | 3.72% |
| 2022 Q3 | 7.75 Million CAD | -78.47% |
| 2022 Q1 | 34.73 Million CAD | 18.67% |
| 2022 Q4 | 11.53 Million CAD | 48.71% |
| 2022 FY | 11.53 Million CAD | -60.59% |
| 2021 Q2 | 14.94 Million CAD | 23.08% |
| 2021 Q1 | 12.14 Million CAD | 1126.77% |
| 2021 Q3 | 24.35 Million CAD | 62.9% |
| 2021 Q4 | 29.26 Million USD | 20.2% |
| 2021 FY | 29.26 Million USD | 2856.36% |
| 2020 Q2 | 1.06 Million CAD | -6.34% |
| 2020 Q4 | 990 Thousand CAD | -2.75% |
| 2020 Q3 | 1.01 Million CAD | -4.23% |
| 2020 Q1 | 1.13 Million CAD | 27.38% |
| 2020 FY | 990 Thousand CAD | -5.71% |
| 2019 Q1 | 1.79 Million CAD | 3490.0% |
| 2019 FY | 1.05 Million CAD | 0.0% |
| 2019 Q2 | 873 Thousand CAD | -51.36% |
| 2019 Q3 | 872 Thousand CAD | -0.11% |
| 2019 Q4 | 891 Thousand CAD | 2.18% |
| 2018 Q1 | - CAD | -100.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | 50 Thousand CAD | 0.0% |
| 2017 Q2 | 6602.00 CAD | 2.5% |
| 2017 Q4 | 31.81 Thousand CAD | 0.68% |
| 2017 Q3 | 31.6 Thousand CAD | 378.67% |
| 2017 Q1 | 6441.00 CAD | 0.0% |
| 2017 FY | - CAD | -100.0% |
| 2016 FY | 6441.00 CAD | 8.42% |
| 2015 FY | 5941.00 CAD | 18.82% |
| 2014 Q3 | 77.5 Thousand CAD | 39.64% |
| 2014 FY | 5000.00 CAD | -82.76% |
| 2014 Q1 | 29 Thousand CAD | 262.5% |
| 2014 Q4 | 5000.00 CAD | -93.55% |
| 2014 Q2 | 55.5 Thousand CAD | 91.38% |
| 2013 FY | 29 Thousand CAD | -3.33% |
| 2013 Q4 | 8000.00 CAD | 0.0% |
| 2013 Q3 | - CAD | -100.0% |
| 2013 Q2 | 30 Thousand CAD | 0.0% |
| 2013 Q1 | 30 Thousand CAD | 0.0% |
| 2012 FY | 30 Thousand CAD | -85.0% |
| 2012 Q1 | 200 Thousand CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q2 | - CAD | -100.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | 200 Thousand CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2006 Q4 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 Q3 | - CAD | 0.0% |
| 2005 Q4 | - CAD | 0.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | - CAD | 0.0% |
| 2005 Q3 | - CAD | 0.0% |
| 2005 Q2 | - CAD | 0.0% |
| 2004 Q3 | - CAD | 0.0% |
| 2004 Q4 | - CAD | 0.0% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 FY | - CAD | 0.0% |
| 2004 Q2 | - CAD | 0.0% |
| 2003 Q3 | - CAD | -100.0% |
| 2003 Q2 | 175 Thousand CAD | 0.0% |
| 2003 FY | - CAD | 0.0% |
| 2003 Q4 | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 97.452% |
| Theratechnologies Inc. | 58.96 Million USD | 76.628% |
| Safety Shot Inc | 1.54 Million USD | -789.75% |
| Cosmos Health Inc. | 12.42 Million USD | -10.931% |
| Cronos Group Inc. | 2.53 Million USD | -442.612% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 98.074% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 62.057% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 88.453% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -151.384% |
| ProPhase Labs, Inc. | 21.38 Million USD | 35.538% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -2166.776% |
| Dynavax Technologies Corporation | 256.91 Million USD | 94.636% |
| Radius Health, Inc. | 365.31 Million USD | 96.227% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -420.575% |
| Alvotech | 1.07 Billion USD | 98.719% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1995.468% |
| Alpha Teknova, Inc. | 30.45 Million USD | 54.751% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 18.633% |
| SCYNEXIS, Inc. | 15.08 Million USD | 8.607% |
| Harrow Health, Inc. | 190.5 Million USD | 92.765% |
| Biofrontera Inc. | 5.39 Million USD | -155.269% |
| DURECT Corporation | 20.74 Million USD | 33.568% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 66.812% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 95.629% |
| OptiNose, Inc. | 131.74 Million USD | 89.539% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -1074.93% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 86.054% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 25.214% |
| SIGA Technologies, Inc. | 1.46 Million USD | -841.388% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 89.428% |
| Shineco, Inc. | 29.65 Million USD | 53.528% |
| Phibro Animal Health Corporation | 525.45 Million USD | 97.377% |
| Procaps Group S.A. | 285.93 Million USD | 95.18% |
| TherapeuticsMD, Inc. | 8 Million USD | -72.167% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -22944.125% |
| Viatris Inc. | 18.12 Billion USD | 99.924% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1995.468% |
| Rockwell Medical, Inc. | 13.43 Million USD | -2.552% |
| Incannex Healthcare Limited | 373 Thousand USD | -3594.906% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 8.903% |
| Tilray Brands, Inc. | 387.31 Million USD | 96.442% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 97.956% |
| PetIQ, Inc. | 468.3 Million USD | 97.057% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 96.783% |
| Journey Medical Corporation | 17.73 Million USD | 22.267% |
| Alimera Sciences, Inc. | 67.39 Million USD | 79.552% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -66.518% |
| Assertio Holdings, Inc. | 40.91 Million USD | 66.313% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -1167.084% |
| Embecta Corp. | 1.63 Billion USD | 99.159% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1234.024% |
| Procaps Group, S.A. | 285.93 Million USD | 95.18% |
| PainReform Ltd. | 86 Thousand USD | -15925.581% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 61.05% |
| Hempacco Co., Inc. | 13.72 Million USD | -0.419% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 97.648% |
| Alvotech | 1.07 Billion USD | 98.719% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 97.766% |
| Kamada Ltd. | 8.74 Million USD | -57.527% |
| Indivior PLC | 281.6 Million USD | 95.106% |
| Currenc Group, Inc. | 31.94 Million USD | 56.855% |
| Evoke Pharma, Inc. | 5 Million USD | -175.64% |
| Flora Growth Corp. | 3.67 Million USD | -275.327% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1234.024% |
| Evolus, Inc. | 126.54 Million USD | 89.109% |
| HUTCHMED (China) Limited | 86.13 Million USD | 83.999% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 97.79% |
| Akanda Corp. | 3.99 Million USD | -244.654% |